Pyrazolam 3MG Pellets

PRODUCT DESCRIPTION

Introduction

Pyrazolam is a psychoactive benzodiazepine compound belonging to the class of central nervous system (CNS) depressants. Originally synthesized in the 1970s, it is derivative of benzodiazepine structurally related to alprazolam and bromazepam. In research contexts, Pyrazolam appears most commonly in solid pellet form, here specifically as 3MG pellets. It is predominantly used for laboratory research purposes and is not intended for human consumption or medicinal use. The pellets provide a consistent, measured dose for analytical studies. The compound is characterized as a crystalline solid with distinctive molecular features that contribute to its chemical and pharmacological profile.

Chemical Properties and Specifications

Structural and Molecular Characteristics

• Chemical Formula: C1616H1212BrN55

• Molecular Weight: 354.2 g/mol

• CAS Number: 39243-02-2

• IUPAC Name: 8-Bromo-1-methyl-6-(pyridin-2-yl)-4H-triazolo[4,3-a]benzodiazepine

• Synonyms: Amuchin, Pirazolam, 8-Bromo-1-methyl-6-(2-pyridinyl)-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine

Physical Properties and Purity Standards

• Appearance: Crystalline solid or pellet form in this specific product presentation

• Purity: ≥99% pure as per laboratory standards for research-grade material

• Solubility: Soluble in dimethylformamide (DMF) at 30 mg/mL, dimethyl sulfoxide (DMSO) at 20 mg/mL, ethanol at 10 mg/mL, methanol at 1 mg/mL, and partially soluble in a DMF:PBS (phosphate-buffered saline) mixture at 0.5 mg/mL.

• Storage Recommendations: Store the pellets at -20°C to maintain the compound’s stability and integrity. Avoid repeated freeze-thaw cycles by aliquoting if dissolved for stock solutions.

Pharmacological Profile and Mechanism of Action

Proposed Mechanism of Action

Pyrazolam acts primarily as a modulator of the gamma-aminobutyric acid type A (GABAAA) receptor, with a high selectivity for the α2 and α3 subunits of this receptor. This results in a depressant effect on the central nervous system. Unlike some benzodiazepines, Pyrazolam is notable for being excreted largely unchanged in the urine, indicating minimal metabolic breakdown.

Research Applications

Due to its unique receptor subtype selectivity and pharmacokinetic profile (elimination half-life around 17 hours), Pyrazolam is employed in neurological and pharmacological research that seeks to elucidate the actions of GABAergic compounds on CNS function, receptor subtype interactions, and potential implications for anxiety, sedation, and other neuropsychiatric conditions.

Comparative Analysis with Related Compounds

Comparisons

Pyrazolam is structurally similar to alprazolam and bromazepam but differs in metabolism and receptor selectivity. Unlike alprazolam, Pyrazolam does not produce detectable metabolites in human serum, supporting distinct pharmacokinetic properties. It is considered a “designer benzodiazepine,” emerging in recent years as a compound of interest in forensic and research arenas.

Advantages for Research

The unique receptor targeting profile makes Pyrazolam advantageous for studies differentiating between benzodiazepine effects on GABA receptor subtypes. Its high purity and stable pellet formulation allow for precise dosing in experimental protocols.

Safety and Handling Guidelines

Laboratory Safety

Handle Pyrazolam pellets with standard laboratory protective equipment including gloves, lab coats, and eye protection. Use in well-ventilated areas or fume hoods to avoid inhalation exposure. Avoid ingestion and skin contact.

Disposal and Environmental Considerations

Dispose of Pyrazolam waste following institutional hazardous chemical waste protocols. Do not release into the environment. Ensure waste is collected for incineration or treatment consistent with regulatory laws.

Regulatory Status

Pyrazolam is classified as a research chemical and is not approved for human therapeutic use. Regulations vary by country; it is subject to controlled substance laws in many jurisdictions, particularly due to its pharmacological effects and designer drug status.

Frequently Asked Questions (FAQs)

1. What is Pyrazolam used for in research?
   Pyrazolam is chiefly used to study GABAAA receptor subtypes, CNS depressant activity, and benzodiazepine pharmacology.

2. Is Pyrazolam metabolized in the body?
   Research indicates Pyrazolam is excreted largely unchanged, differentiating it from other benzodiazepines metabolized in the liver.

3. What solvents are best for dissolving Pyrazolam?
   It is most soluble in DMF, DMSO, ethanol, and methanol, with specific concentrations noted to prepare stock solutions.

4. How should Pyrazolam be stored?
   Store at -20°C in a dry environment, avoiding repeated freeze-thawing cycles to preserve chemical integrity.

5. Is Pyrazolam legal?
   Its legal status varies globally; it is typically restricted or controlled under drug analog or designer drug regulations.

Conclusion

Pyrazolam 3MG Pellets are a high-purity benzodiazepine research compound used primarily in neurological and pharmacological studies of GABA receptor modulation. Its specific molecular characteristics, metabolic stability, and receptor selectivity make it a valuable tool for scientists investigating CNS depressants and benzodiazepine receptor subtype interactions. Proper handling and storage are essential to maintain its stability, and compliance with regulatory requirements is mandatory for lawful use in research.